Skip to main content
Erschienen in: Inflammation 2/2018

04.01.2018 | ORIGINAL ARTICLE

Anti-inflammatory Effect of DNA Polymeric Molecules in a Cell Model of Osteoarthritis

verfasst von: Ahreum Baek, MinGi Kim, Sung Hoon Kim, Sung-Rae Cho, Hyun Jung Kim

Erschienen in: Inflammation | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

The DNA polymeric molecules polydeoxynucleotide (PDRN) and polynucleotide (PN) can be used as new alternative treatment for osteoarthritis (OA); however, the underlying mechanisms are not fully understood. In this study, we investigated the effect of PDRN and PN on gene-expression profiles in a cell model of OA using transcriptome analysis. Under hypoxic conditions, human chondrosarcoma cells were stressed for 24 h in the presence of interleukin (IL)-1β and subsequently treated with PDRN, PN, or hyaluronic acid (HA) for another 24 h, followed by transcriptome analysis. The results of the transcriptome study comprising differentially expressed genes were analyzed using the Database of Annotation Visualization and Integrated Discovery program, which yielded Kyoto Encyclopedia of Genes and Genomes pathways. Toll-like receptor (TLR)- and nucleotide-binding oligomerization domain-like receptor (NLR)-signaling pathways were related between the IL-1β group and the group treated with DNA polymeric molecules. The genes involved in the TLR- and NLR-signaling pathways were validated using real-time quantitative polymerase chain reaction and western blot. Among these genes, IL-6, IL-1β, IL-8, and chemokine (C-C motif) ligand 3 were dramatically upregulated in the IL-1β group, but significantly downregulated in the group treated with DNA polymeric molecules. Specifically, PN treatment resulted in a greater decrease in the expression of these genes as compared with PDRN treatment. Both PDRN and PN treatments were involved in the anti-inflammatory response associated with OA progression, with PN treatment exhibiting additional anti-inflammatory properties relative to PDRN treatment. These results provide insight into potential therapeutic approaches involving PDRN and PN treatment of OA.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Civinini, R., L. Nistri, C. Martini, B. Redl, G. Ristori, and M. Innocenti. 2013. Growth factors in the treatment of early osteoarthritis. Clin Cases Miner Bone Metab 10 (1): 26–29.PubMedPubMedCentral Civinini, R., L. Nistri, C. Martini, B. Redl, G. Ristori, and M. Innocenti. 2013. Growth factors in the treatment of early osteoarthritis. Clin Cases Miner Bone Metab 10 (1): 26–29.PubMedPubMedCentral
3.
Zurück zum Zitat Giarratana, L.S., B.M. Marelli, C. Crapanzano, et al. 2014. A randomized double-blind clinical trial on the treatment of knee osteoarthritis: the efficacy of polynucleotides compared to standard hyaluronian viscosupplementation. The Knee 21 (3): 661–668.CrossRefPubMed Giarratana, L.S., B.M. Marelli, C. Crapanzano, et al. 2014. A randomized double-blind clinical trial on the treatment of knee osteoarthritis: the efficacy of polynucleotides compared to standard hyaluronian viscosupplementation. The Knee 21 (3): 661–668.CrossRefPubMed
4.
Zurück zum Zitat Bonnet, C.S., and D.A. Walsh. 2005. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44 (1): 7–16.CrossRef Bonnet, C.S., and D.A. Walsh. 2005. Osteoarthritis, angiogenesis and inflammation. Rheumatology (Oxford) 44 (1): 7–16.CrossRef
5.
Zurück zum Zitat Orlowsky, E.W., and V.B. Kraus. 2015. The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive. The Journal of Rheumatology 42 (3): 363–371.CrossRefPubMedPubMedCentral Orlowsky, E.W., and V.B. Kraus. 2015. The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive. The Journal of Rheumatology 42 (3): 363–371.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Vincent, T.L. 2013. Targeting mechanotransduction pathways in osteoarthritis: a focus on the pericellular matrix. Current Opinion in Pharmacology 13 (3): 449–454.CrossRefPubMed Vincent, T.L. 2013. Targeting mechanotransduction pathways in osteoarthritis: a focus on the pericellular matrix. Current Opinion in Pharmacology 13 (3): 449–454.CrossRefPubMed
7.
Zurück zum Zitat Torrero, J.I., and C. Martinez. 2015. New developments in the treatment of osteoarthritis—focus on biologic agents. Open Access Rheumatol 7: 33–43.CrossRefPubMedPubMedCentral Torrero, J.I., and C. Martinez. 2015. New developments in the treatment of osteoarthritis—focus on biologic agents. Open Access Rheumatol 7: 33–43.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Liu-Bryan, R., and R. Terkeltaub. 2015. Emerging regulators of the inflammatory process in osteoarthritis. Nature Reviews Rheumatology 11 (1): 35–44.CrossRefPubMed Liu-Bryan, R., and R. Terkeltaub. 2015. Emerging regulators of the inflammatory process in osteoarthritis. Nature Reviews Rheumatology 11 (1): 35–44.CrossRefPubMed
10.
Zurück zum Zitat Kapoor, M., J. Martel-Pelletier, D. Lajeunesse, J.P. Pelletier, and H. Fahmi. 2011. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nature Reviews Rheumatology 7 (1): 33–42.CrossRefPubMed Kapoor, M., J. Martel-Pelletier, D. Lajeunesse, J.P. Pelletier, and H. Fahmi. 2011. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nature Reviews Rheumatology 7 (1): 33–42.CrossRefPubMed
11.
Zurück zum Zitat Ortolano, G.A., and B. Wenz. 2014. A review of the pathogenesis of osteoarthritis and the use of intra-articular platelet therapy for joint disease in animals and humans. Bone and Tissue Regeneration Insights 5: 1–13.CrossRef Ortolano, G.A., and B. Wenz. 2014. A review of the pathogenesis of osteoarthritis and the use of intra-articular platelet therapy for joint disease in animals and humans. Bone and Tissue Regeneration Insights 5: 1–13.CrossRef
12.
Zurück zum Zitat Thellung, S., T. Florio, A. Maragliano, G. Cattarini, and G. Schettini. 1999. Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: involvement of A2 purinergic receptor subtypes. Life Sciences 64 (18): 1661–1674.CrossRefPubMed Thellung, S., T. Florio, A. Maragliano, G. Cattarini, and G. Schettini. 1999. Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: involvement of A2 purinergic receptor subtypes. Life Sciences 64 (18): 1661–1674.CrossRefPubMed
14.
Zurück zum Zitat Linden, J. 2005. Adenosine in tissue protection and tissue regeneration. Molecular Pharmacology 67 (5): 1385–1387.CrossRefPubMed Linden, J. 2005. Adenosine in tissue protection and tissue regeneration. Molecular Pharmacology 67 (5): 1385–1387.CrossRefPubMed
15.
Zurück zum Zitat Vanelli, R., P. Costa, S.M. Rossi, and F. Benazzo. 2010. Efficacy of intra-articular polynucleotides in the treatment of knee osteoarthritis: a randomized, double-blind clinical trial. Knee Surgery, Sports Traumatology, Arthroscopy 18 (7): 901–907.CrossRefPubMed Vanelli, R., P. Costa, S.M. Rossi, and F. Benazzo. 2010. Efficacy of intra-articular polynucleotides in the treatment of knee osteoarthritis: a randomized, double-blind clinical trial. Knee Surgery, Sports Traumatology, Arthroscopy 18 (7): 901–907.CrossRefPubMed
16.
Zurück zum Zitat Gebauer, M., J. Saas, F. Sohler, et al. 2005. Comparison of the chondrosarcoma cell line SW1353 with primary human adult articular chondrocytes with regard to their gene expression profile and reactivity to IL-1beta. Osteoarthritis and Cartilage 13 (8): 697–708.CrossRefPubMed Gebauer, M., J. Saas, F. Sohler, et al. 2005. Comparison of the chondrosarcoma cell line SW1353 with primary human adult articular chondrocytes with regard to their gene expression profile and reactivity to IL-1beta. Osteoarthritis and Cartilage 13 (8): 697–708.CrossRefPubMed
17.
Zurück zum Zitat Kim, M.S., J.H. Yu, M.Y. Lee, et al. 2016. Differential expression of extracellular matrix and adhesion molecules in fetal-origin amniotic epithelial cells of preeclamptic pregnancy. PLoS One 11 (5): e0156038.CrossRefPubMedPubMedCentral Kim, M.S., J.H. Yu, M.Y. Lee, et al. 2016. Differential expression of extracellular matrix and adhesion molecules in fetal-origin amniotic epithelial cells of preeclamptic pregnancy. PLoS One 11 (5): e0156038.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Won, Y.H., M.Y. Lee, Y.C. Choi, et al. 2016. Elucidation of relevant neuroinflammation mechanisms using gene expression profiling in patients with amyotrophic lateral sclerosis. PLoS One 11 (11): e0165290.CrossRefPubMedPubMedCentral Won, Y.H., M.Y. Lee, Y.C. Choi, et al. 2016. Elucidation of relevant neuroinflammation mechanisms using gene expression profiling in patients with amyotrophic lateral sclerosis. PLoS One 11 (11): e0165290.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Baek, A., S.R. Cho, and S.H. Kim. 2017. Elucidation of gene expression patterns in the brain after spinal cord injury. Cell Transplantation 26 (7): 1286–1300.CrossRefPubMedPubMedCentral Baek, A., S.R. Cho, and S.H. Kim. 2017. Elucidation of gene expression patterns in the brain after spinal cord injury. Cell Transplantation 26 (7): 1286–1300.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25 (4): 402–408.CrossRefPubMed Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25 (4): 402–408.CrossRefPubMed
21.
Zurück zum Zitat Malemud, C.J. 2010. Anticytokine therapy for osteoarthritis: evidence to date. Drugs & Aging 27 (2): 95–115.CrossRef Malemud, C.J. 2010. Anticytokine therapy for osteoarthritis: evidence to date. Drugs & Aging 27 (2): 95–115.CrossRef
22.
Zurück zum Zitat Akkiraju, H., and A. Nohe. 2015. Role of chondrocytes in cartilage formation, progression of osteoarthritis and cartilage regeneration. J Dev Biol 3 (4): 177–192.CrossRefPubMedPubMedCentral Akkiraju, H., and A. Nohe. 2015. Role of chondrocytes in cartilage formation, progression of osteoarthritis and cartilage regeneration. J Dev Biol 3 (4): 177–192.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Wojdasiewicz, P., L.A. Poniatowski, and D. Szukiewicz. 2014. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators of Inflammation 2014: 561459.CrossRefPubMedPubMedCentral Wojdasiewicz, P., L.A. Poniatowski, and D. Szukiewicz. 2014. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators of Inflammation 2014: 561459.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Afonso, V., R. Champy, D. Mitrovic, P. Collin, and A. Lomri. 2007. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint, Bone, Spine 74 (4): 324–329.CrossRefPubMed Afonso, V., R. Champy, D. Mitrovic, P. Collin, and A. Lomri. 2007. Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint, Bone, Spine 74 (4): 324–329.CrossRefPubMed
26.
Zurück zum Zitat Gerard, C., and B.J. Rollins. 2001. Chemokines and disease. Nature Immunology 2 (2): 108–115.CrossRefPubMed Gerard, C., and B.J. Rollins. 2001. Chemokines and disease. Nature Immunology 2 (2): 108–115.CrossRefPubMed
28.
Zurück zum Zitat Haringman, J.J., J. Ludikhuize, and P.P. Tak. 2004. Chemokines in joint disease: the key to inflammation? Annals of the Rheumatic Diseases 63 (10): 1186–1194.CrossRefPubMedPubMedCentral Haringman, J.J., J. Ludikhuize, and P.P. Tak. 2004. Chemokines in joint disease: the key to inflammation? Annals of the Rheumatic Diseases 63 (10): 1186–1194.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Cronstein, B.N. 1994. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol (1985) 76 (1): 5–13.CrossRef Cronstein, B.N. 1994. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol (1985) 76 (1): 5–13.CrossRef
30.
Zurück zum Zitat Gomez, G., and M.V. Sitkovsky. 2003. Targeting G protein-coupled A2a adenosine receptors to engineer inflammation in vivo. The International Journal of Biochemistry & Cell Biology 35 (4): 410–414.CrossRef Gomez, G., and M.V. Sitkovsky. 2003. Targeting G protein-coupled A2a adenosine receptors to engineer inflammation in vivo. The International Journal of Biochemistry & Cell Biology 35 (4): 410–414.CrossRef
31.
Zurück zum Zitat Hasko, G., C. Szabo, Z.H. Nemeth, V. Kvetan, S.M. Pastores, and E.S. Vizi. 1996. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. Journal of Immunology 157 (10): 4634–4640. Hasko, G., C. Szabo, Z.H. Nemeth, V. Kvetan, S.M. Pastores, and E.S. Vizi. 1996. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. Journal of Immunology 157 (10): 4634–4640.
32.
Zurück zum Zitat Link, A.A., T. Kino, J.A. Worth, et al. 2000. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. Journal of Immunology 164 (1): 436–442.CrossRef Link, A.A., T. Kino, J.A. Worth, et al. 2000. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. Journal of Immunology 164 (1): 436–442.CrossRef
33.
Zurück zum Zitat Fakhari, A., and C. Berkland. 2013. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment. Acta Biomaterialia 9 (7): 7081–7092.CrossRefPubMedPubMedCentral Fakhari, A., and C. Berkland. 2013. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment. Acta Biomaterialia 9 (7): 7081–7092.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Zheng Shu, X., Y. Liu, F.S. Palumbo, Y. Luo, and G.D. Prestwich. 2004. In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 25 (7–8): 1339–1348.CrossRefPubMed Zheng Shu, X., Y. Liu, F.S. Palumbo, Y. Luo, and G.D. Prestwich. 2004. In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 25 (7–8): 1339–1348.CrossRefPubMed
35.
Zurück zum Zitat Vejlens, L. 1971. Glycosaminoglycans of human bone tissue. I. Pattern of compact bone in relation to age. Calcified Tissue Research 7 (2): 175–190. Vejlens, L. 1971. Glycosaminoglycans of human bone tissue. I. Pattern of compact bone in relation to age. Calcified Tissue Research 7 (2): 175–190.
Metadaten
Titel
Anti-inflammatory Effect of DNA Polymeric Molecules in a Cell Model of Osteoarthritis
verfasst von
Ahreum Baek
MinGi Kim
Sung Hoon Kim
Sung-Rae Cho
Hyun Jung Kim
Publikationsdatum
04.01.2018
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 2/2018
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-017-0722-2

Weitere Artikel der Ausgabe 2/2018

Inflammation 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.